ENTITY

OSE Immuno (OSE FP)

31
Analysis
Health CareFrance
OSE Immunotherapeutics SA is a biotechnology company based in France, developing immunotherapy products against invasive/metastatic late-stage cancers.
more
Refresh
bullishOSE Immuno
12 Apr 2024 19:10Issuer-paid

OSE Immunotherapeutics - Funding accelerates Tedopi clinical development

Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public...

Share
bullishOSE Immuno
03 Apr 2024 01:10Issuer-paid

OSE Immunotherapeutics - Pipeline momentum builds into FY24

OSE Immunotherapeutics’ (OSE’s) FY23 update summarised an active period for its clinical pipeline that was capped by the post-period $713m deal...

Share
bullishOSE Immuno
20 Mar 2024 01:10Issuer-paid

OSE Immunotherapeutics - One step closer to key data readouts

OSE Immunotherapeutics has announced the completion of patient enrolment in its Phase II CoTikiS trial, marking another step in the clinical...

Share
bullishOSE Immuno
29 Feb 2024 01:10Issuer-paid

OSE Immunotherapeutics - Confidence boost with AbbVie partnership

OSE Immunotherapeutics has announced a global licence and collaboration agreement with AbbVie to develop OSE-230, a novel monoclonal antibody, for...

Share
bullishOSE Immuno
28 Feb 2024 01:10Issuer-paid

OSE Immunotherapeutics - Encouraging OSE-279 clinical update

At the 2024 ESMO Targeted Anticancer Therapies Congress, OSE Immunotherapeutics (OSE) presented encouraging interim results from the Phase I/II...

Share
x